1361951-15-6 Usage
General Description
TP-3654 is a second-generation Pim kinase inhibitor being developed for the treatment of various cancers and other health conditions. Pim kinases are enzymes linked to the growth and survival of cancer cells, and inhibiting these enzymes can potentially disrupt the progression of the disease. TP-3654 is the successor to an earlier compound, SGI-1776, and has shown improved efficacy and safety profiles in preclinical studies. Initial experiments suggest that TP-3654 has anti-cancer properties, including the ability to inhibit tumor growth and selectively target cancer cells. However, further research and clinical trials are necessary to fully elucidate its exact mechanisms and potential applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1361951-15-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,1,9,5 and 1 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1361951-15:
(9*1)+(8*3)+(7*6)+(6*1)+(5*9)+(4*5)+(3*1)+(2*1)+(1*5)=156
156 % 10 = 6
So 1361951-15-6 is a valid CAS Registry Number.
1361951-15-6Relevant articles and documents
FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
-
Paragraph 00515; 00517, (2020/08/28)
Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I): (I) or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.
HETEROCYCLIC PROTEIN KINASE INHIBITORS
-
, (2013/03/26)
The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
